VERIGENE® Gastrointestinal Infection Tests | VERIGENE® Enteric Pathogens Test

The VERIGENE® Enteric Pathogens Test (EP) is a rapid molecular panel that detects bacteria, viruses, and toxins that commonly cause acute diarrhea

The Benefits of the Enteric Pathogens Test


VERIGENE® EP is a rapid, easy to use, and cost-effective alternative to traditional stool diagnostics that delivers clinical, economic, and workflow benefits to hospitals and laboratories.


Clinical Benefits


  • Therapeutic—Results can improve patient management decision making, thereby minimizing use of inappropriate or unnecessary drugs
  • Accurate—Stool culture is less sensitive than molecular methods, with molecular testing detecting almost three times as many infections in the same set of samples
  • Public Health—Results can trigger outbreak investigations
  • Diagnostic—Results can mitigate further unnecessary downstream testing
  • Psychologic—Results can lead to earlier peace of mind for the patient and physician once the causative pathogen has been identified


Workflow Benefits


  • Nearly 95% of all stool samples are negative, yet still require similar hands-on time by the technologist (1-2 hours) and incubation time (72-96 hours) per sample as a positive sample
  • Confirmation of a negative stool sample takes only two hours on the VERIGENE® System, allowing laboratories to reallocate technologist time to other priorities within the lab


Economic Benefits


  • Lower cost from reduced use of inappropriate or unnecessary antimicrobial or antiviral drugs
  • Potential reduction in length of stay and length of isolation for patients in the hospital
  • Reduced cost of sample send-out to reference laboratories
  • Reallocation of technician time



View our webinar titled “Molecular GI Testing – An Approach Based on Clinical Guidelines.” This program discusses the new guidelines for the diagnosis of infectious diarrhea and how multiplexed molecular GI testing can have a positive impact on patient care. Additionally, the speakers shared best practices for implementing the VERIGENE® Enteric Pathogens Test (EP), to ensure their laboratories recognized these clinical, operational, and economic benefits. Click here for the program summary



View More Assays Available on Our VERIGENE® Menu:


VERIGENE® Gram-Negative Blood Culture AssayVERIGENE® Gram-Positive Blood Culture AssayVERIGENE® C. diff AssayVERIGENE® Respiratory Pathogens Flex Test




Enteric Pathogens Test Specifications


Targets U.S./FDA-Cleared Outside U.S.
Campylobacter Group
Salmonella spp.
Shigella spp.
Vibrio Group
Yersinia enterocolitica
Shiga Toxin 1 (stx1)
Shiga Toxin 2 (stx2)


Key Features
Automation Sample to Result
Instrumentation VERIGENE Reader and Processor SP
Workflow On-Demand and Scalable
Sample Type Stool Preserved in Cary-Blair
Pipetting Steps One
Hands-On Time <5 minutes
Run Time <2 hours



Ordering Information


Luminex Online Order Management
Email: [email protected]
Phone: +31 (0)73 800 1900
Fax: +31 (0)73 800 1998
Product Name Kit Size Registration
Part Number
VERIGENE® Enteric Pathogens Nucleic Acid Test (EP) Kit 20 EP Test Cartridges
20 Extraction Trays
CE Marked
VERIGENE® Enteric Pathogens Nucleic Acid Test (EP) Amplification Kit

20 EP Amplification Trays US-IVD
CE Marked
VERIGENE® Sample Processor SP 1 unit US-IVD
CE Marked
VERIGENE® Reader 1 unit US-IVD
CE Marked





Time and Motion Study: Molecular Testing with VERIGENE® Enteric Pathogens (EP) Test Accelerates Results
for GI Infection Samples
White Paper


VERIGENE® Enteric Pathogens Nucleic Acid Test (EP)Product Information

Conventional Stool vs VERIGENE Enteric Pathogens (EP) Test Workflow ComparisonFlyer

Practice Guidelines for the Management of Infectious DiarrheaIDSA Guidelines

Evaluation of Costs, Technologists Time, and Turn-Around Times for Conventional Stool CulturesCase Study

Evaluation of the VERIGENE EP IUO Test for the Rapid Detection of Bacterial and Viral Causes of Gastrointestinal InfectionPoster

Evaluation of the VERIGENE Enteric Pathogens (EP) Nucleic Acid Test for the Identification of Bacterial and Viral Agents of Diarrhea Directly from Stool SpecimensAbstract

A Comparison of Three Multiplex Molecular Panels for the Detection of Gastrointestinal PathogensAbstract

Fecal Matters: Clinical Impact and Cost Effectiveness of Molecular GI Pathogen TestingWebinar

Molecular Testing for GI Pathogens: Cost-Effectiveness, Clinical Impact and Lab ImplementationWebinar

Justification, Validation and Implementation Best Practices for Multiplex Molecular Infectious Disease TestsWebinar


Clinical labs need flexibility and scalability in their GI assays to deliver optimal results to physicians. Luminex offers targeted diagnostic options for nosocomial diarrhea and syndromic panels for community acquired/traveler’s diarrhea that align with recommended guidelines.
Read More

  1. Herikstad H, Yang S, Van Gilder TJ, et al. A population-based estimate of the burden of diarrheal illness in the United States: FoodNet, 1996-7. Epidemiol Infect 2002; 129:9-17.


For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The VERIGENE® Enteric Pathogens Nucleic Acid Test (EP) is a multiplexed, qualitative test for simultaneous detection and identification of common pathogenic enteric bacteria, viruses, and genetic virulence markers from liquid or soft stool preserved in Cary-Blair medium, collected from individuals with signs and symptoms of gastrointestinal infection. The test is performed on the automated VERIGENE System utilizing reverse transcription (RT), polymerase chain reaction (PCR), and array hybridization to detect specific gastrointestinal microbial nucleic acid gene sequences associated with the following pathogenic bacteria and viruses: Campylobacter Group (composed of C. coli, C. jejuni, and C. lari), Salmonella species, Shigella species (including S. dysenteriae, S. boydii, S. sonnei, and S. flexneri), Vibrio Group (composed of V. cholerae and V. parahaemolyticus), Yersinia enterocolitica, Norovirus GI/GII, Rotavirus A.

In addition, EP detects the Shiga toxin 1 gene and Shiga toxin 2 gene virulence markers. Shiga toxin producing E. coli (STEC) typically harbor one or both genes that encode for Shiga toxins 1 and 2.

EP is indicated as an aid in the diagnosis of specific agents of gastrointestinal illness, in conjunction with other clinical, laboratory, and epidemiological information; however, is not to be used to monitor these infections. EP also aids in the detection and identification of acute gastroenteritis in the context of outbreaks.

Due to the limited number of positive specimens collected for certain organisms during the prospective clinical study, performance characteristics for Yersinia enterocolitica, Vibrio Group and Shigella species were primarily established with contrived specimens.

Concomitant culture is necessary for organism recovery and further typing of bacterial agents.

EP results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Confirmed positive results do not rule out co-infection with other organisms that are not detected by this test, and may not be the sole or definitive cause of patient illness. Negative EP results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test or non-infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn’s disease.